Overview

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Status:
Terminated

Trial end date:
2017-06-30

Target enrollment:

Participant gender:

Summary

To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.

Phase:

Phase 3

Details

Lead Sponsor:

Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, Ltd.